Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT + Durvalumab + Tremelimumab in Oligometastatic NSCLC
NCT03275597Phase 1Terminated
- Sponsor
- University of Wisconsin–Madison
- Start
- Feb 2018
- Primary completion
- Jul 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of durvalumab and tremelimumab in non-small cell lung cancer (NSCLC), sponsored by University of Wisconsin–Madison. Primary endpoint: Safety and tolerability of SBRT followed by combined durvalumab and tremelimumab up to 3 years. Started Feb 2018; status: terminated.
02
Drugs
durvalumabtremelimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03275597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03275597.